



Vivimed

Date: 27/05/2017

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Sub.: Outcome of the Board Meeting held on May 27, 2017

Dear Sir / Madam,

We wish to inform you that:

1. The Board of Directors (the Board") at its meeting held today i.e. May 27, 2017 has considered and approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2017. Please find enclosed said Audited Results along with Audit Report and Declaration as per Regulation 33 of the SEBI (LODR) (Amendment) Regulations, 2016
2. The Board has also recommended, subject to the approval of shareholders, payment of Dividend of Rs.0.40/- (Forty paise) per equity share of Rs.2/- each (20%), to the equity shareholders of the Company for the Financial Year 2016-2017. The said dividend, if approved by shareholders, will be credited /despatched to those members entitled thereto as per record date/Book closure date to be decided subsequently.
3. The meeting of the Board of Directors of the Company commenced at 2:30 P.M and concluded at 10.00 P.M .

Please take the above on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For Vivimed Labs Ltd


Santosh Varalwar
Managing Director



Vivimed Labs Ltd. (Corporate Office)

CIN: L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India.

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com | www.vivimedlabs.com

VIVIMED LABS LIMITED
AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2017

Rs. in Lakhs

| Sl. No. | Particulars | Quarter Ended | | | Year ended 31.03.2017 | Previous Year ended 31.03.2016 |
|---------|---|------------------|------------------|------------------|--------------------------|-----------------------------------|
| | | 31.03.2017 | 31.12.2016 | 31.03.2016 | | |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | Income From Operations | | | | | |
| 1 | Net Sales / Income from Operations (Net of Excise Duty) | 43,668.29 | 36,003.30 | 34,716.22 | 1,46,191.12 | 1,34,562.99 |
| 2 | Other Income | 228.47 | 307.88 | 288.52 | 805.04 | 1,080.98 |
| 3 | Total Revenue (1+2) | 43,896.77 | 36,311.19 | 35,004.74 | 1,46,996.16 | 1,35,643.97 |
| 4 | Expenses | | | | | |
| a | Cost of material consumed | 11,689.84 | 13,827.91 | 15,123.83 | 56,583.13 | 60,969.16 |
| b | Purchases of Stock- in- Trade | - | - | - | - | - |
| c | Changes in inventories of finished goods work in progress and stock-in-Trade | (1,219.08) | (1,291.63) | 1,448.33 | (2,954.62) | 1,435.62 |
| d | Employee Benefit Expenses | 4,769.60 | 5,008.86 | 5,549.99 | 18,934.31 | 17,694.25 |
| e | Finance Costs | 1,802.78 | 1,733.95 | 2,450.79 | 6,551.77 | 8,156.63 |
| f | Depreciation and Amortisation Expenses | 1,259.68 | 1,547.07 | 1,477.06 | 5,827.75 | 6,139.34 |
| g | Other Expenses | 9,795.87 | 8,457.43 | 7,759.18 | 32,457.24 | 31,255.74 |
| | Total Expenses | 28,098.69 | 29,283.59 | 33,809.18 | 1,17,399.58 | 1,25,650.74 |
| 5 | Profit/(Loss) before exceptional items and tax (3-4) | 15,798.08 | 7,027.60 | 1,195.56 | 29,596.58 | 9,993.23 |
| 6 | Exceptional items | - | - | - | - | - |
| 7 | Profit/(Loss) before extraordinary items and tax (5-6) | 15,798.08 | 7,027.60 | 1,195.56 | 29,596.58 | 9,993.23 |
| 8 | Extraordinary items | - | - | - | - | - |
| 9 | Profit/(Loss) before tax (7-8) | 15,798.08 | 7,027.60 | 1,195.56 | 29,596.58 | 9,993.23 |
| 10 | Tax expenses | | | | | |
| | Current Taxes | 4,222.71 | 1,856.79 | (542.88) | 7,409.46 | 1,611.60 |
| | Deferred Taxes | 100.11 | - | 477.76 | 12.72 | 14.32 |
| | | 4,322.82 | 1,856.79 | (65.12) | 7,422.18 | 1,625.93 |
| 11 | Profit/(Loss) for the period from continuing operations (9-10) | 11,475.26 | 5,170.81 | 1,260.68 | 22,174.40 | 8,367.30 |
| 12 | Profit /(Loss) from discontinued operations | - | - | - | - | - |
| 13 | Tax expenses of discontinued operations | - | - | - | - | - |
| 14 | Profit/(Loss) from the discontinued operations(after tax) (12-13) | - | - | - | - | - |
| 15 | Profit/(Loss) for the period /Year | 11,475.26 | 5,170.81 | 1,260.68 | 22,174.40 | 8,367.30 |
| 16 | Minority Interest | - | - | - | - | - |
| 17 | Net Profit / Loss after taxes and Minority Interest (15-16) | 11,475.26 | 5,170.81 | 1,260.68 | 22,174.40 | 8,367.30 |
| 18 | Paid up Equity Share Capital | 1,620.38 | 1,620.38 | 1,620.38 | 1,620.38 | 1,620.38 |
| 19 | Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year | - | - | - | 66,969.33 | 50,400.31 |
| 20 | Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised) | | | | | |
| | (a) Basic | 14.16 | 6.38 | 7.78 | 27.37 | 10.33 |
| | (b) Diluted | 13.74 | 6.19 | 7.55 | 26.55 | 10.02 |

1. The above Consolidated Audited Financial Results for the Quarter & Year ended 31.03.2017 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 27.05.2017

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Finoso Pharma pvt Limited (ii) Vivimed Speciality chemicals pvt Ltd (iii) Vivimed life sciences pvt Ltd and its wholly owned foreign subsidiaries viz(i) Vivimed Labs USA, Inc.,(ii)Vivimed Labs Mauritius Limited (iii) Vivimed Holdings Limited and its stepdown subsidiaries (iv) Vivimed Labs Europe Limited (v) Vivimed Labs UK Limited, (vi) Vivimed Labs Spain, S.L. (vii) Union Quimico Farmaceutica S.A.U., Spain, (viii) Holliday International Limited, UK & (ix) Uquifa Mexico S.A. de C.V.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

5. The income from divestiture of " certain products in speciality chemical division to Clariant India Limited" has been recognised.

6. The income from divestiture of Klarsehen business has been recognised.

7. Vivimed Labs Europe Ltd acquired CCPS held in Vivimed Labs Mauritius Ltd

Place : Hyderabad
Date : 27.05.2017

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR



VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED

Rs. in Lakhs

| Particulars | 3 Months Ended | | | YEAR ENDED | YEAR ENDED |
|---|--------------------|--------------------|--------------------|--------------------|--------------------|
| | 31.03.2017 | 31.12.2016 | 31.03.2016 | 31.03.2017 | 31-03-2016 |
| | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| 1. Segment Revenue (net sales/income from each segment should be disclosed under this head) | | | | | |
| a.Speciality Chemicals Business | 21,482.64 | 7,061.54 | 9,449.86 | 45,152.82 | 37,141.36 |
| b. Pharma Business | 22,185.65 | 28,941.76 | 25,266.36 | 1,01,038.30 | 97,421.63 |
| Total | 43,668.29 | 36,003.30 | 34,716.22 | 1,46,191.12 | 1,34,562.99 |
| Less, Inter Segment Revenue | | | | | |
| Net sales / Income from Operations | 43,668.29 | 36,003.30 | 34,716.22 | 1,46,191.12 | 1,34,562.99 |
| 2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment | | | | | |
| a.Speciality Chemicals Business | 15,301.30 | 1,419.05 | 1,212.21 | 21,710.76 | 6,796.84 |
| b. Pharma Business | 2,299.55 | 7,342.50 | 2,434.13 | 14,437.59 | 11,353.02 |
| Total | 17,600.85 | 8,761.55 | 3,646.34 | 36,148.35 | 18,149.87 |
| Less: 1. Interest | 1,802.78 | 1,733.95 | 2,450.79 | 6,551.77 | 8,156.63 |
| 2. Other Un-allocable Expenditure | | | | | |
| 3. Un-allocable Income | | | | | |
| Total Profit Before Tax | 15,798.08 | 7,027.60 | 1,195.55 | 29,596.58 | 9,993.24 |
| 3. Capital Employed | | | | | |
| a.Speciality Chemicals Business | 99,114.25 | 72,216.23 | 84,539.58 | 99,114.25 | 84,539.58 |
| b. Pharma Business | 63,492.83 | 93,253.78 | 70,862.31 | 63,492.83 | 70,862.31 |
| | 1,62,607.08 | 1,65,470.01 | 1,55,401.89 | 1,62,607.08 | 1,55,401.89 |
| a. Segment Assets | 2,06,552.26 | 2,14,624.85 | 2,04,366.82 | 2,06,552.26 | 2,04,366.82 |
| b. Segment Liabilities | 1,34,162.55 | 1,43,790.05 | 1,45,851.57 | 1,34,162.55 | 1,45,851.57 |

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR



Place : Hyderabad
Date : 27.05.2017

VIVIMED LABS LIMITED
AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2017

Rs. in Lakhs

| Sl. No. | Particulars | Quarter Ended | | | Year ended 31.03.2017 | Previous Year ended 31.03.2016 |
|---------|---|------------------|------------------|-----------------|--------------------------|--------------------------------------|
| | | 31.03.2017 | 31.12.2016 | 31.03.2016 | | |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | Income From Operations | | | | | |
| 1 | Net Sales / Income from Operations (Net of Excise Duty) | 22,608.42 | 13,952.42 | 7,953.58 | 56,983.78 | 31,939.36 |
| 2 | Other Income | 164.25 | 51.14 | 67.17 | 234.12 | 98.38 |
| 3 | Total Revenue (1+2) | 22,772.67 | 14,003.56 | 8,020.75 | 57,217.90 | 32,037.74 |
| 4 | Expenses | | | | | |
| a | Cost of material consumed | 3,347.50 | 3,960.25 | 3,274.09 | 18,219.17 | 12,467.66 |
| b | Purchases of Stock- in- Trade | - | - | - | - | - |
| c | Changes in inventories of finished goods work in progress and stock-in-Trade | 463.63 | (138.23) | (12.99) | (226.08) | 686.79 |
| d | Employee Benefit Expenses | 1,120.54 | 999.42 | 645.05 | 4,159.88 | 2,399.35 |
| e | Finance Costs | 1,431.92 | 1,362.26 | 1,200.03 | 5,354.99 | 5,605.93 |
| f | Depreciation and Amortisation Expenses | 505.67 | 755.69 | 534.45 | 2,683.21 | 1,879.24 |
| g | Other Expenses | 2,889.07 | 1,859.83 | 2,144.49 | 8,882.53 | 7,864.80 |
| | Total Expenses | 9,758.33 | 8,799.22 | 7,785.12 | 39,073.70 | 30,903.77 |
| 5 | Profit/(Loss) before exceptional items and tax (3-4) | 13,014.34 | 5,204.35 | 235.63 | 18,144.20 | 1,133.97 |
| 6 | Exceptional items | - | - | - | - | - |
| 7 | Profit/(Loss) before extraordinary items and tax (5-6) | 13,014.34 | 5,204.35 | 235.63 | 18,144.20 | 1,133.97 |
| 8 | Extraordinary items | - | - | - | - | - |
| 9 | Profit/(Loss) before tax (7-8) | 13,014.34 | 5,204.35 | 235.63 | 18,144.20 | 1,133.97 |
| 10 | Tax Expenses | | | | | |
| | Current Taxes | 3,528.75 | 1,184.77 | 39.14 | 4,812.11 | 222.28 |
| | Deferred Taxes | 64.19 | - | 98.89 | 64.19 | 98.89 |
| | Tax Expenses | 3,592.94 | 1,184.77 | 138.03 | 4,876.30 | 321.17 |
| 11 | Profit/(Loss) for the period from continuing operations (9-10) | 9,421.40 | 4,019.58 | 97.60 | 13,267.90 | 812.80 |
| 12 | Profit /(Loss) from discontinued operations | - | - | - | - | - |
| 13 | Tax expenses of discontinued operations | - | - | - | - | - |
| 14 | Profit/(Loss) from the discontinued operations(after tax) (12-13) | - | - | - | - | - |
| 15 | Profit/(Loss) for the period /Year | 9,421.40 | 4,019.58 | 97.60 | 13,267.90 | 812.80 |
| 16 | Minority Interest | - | - | - | - | - |
| 17 | Net Profit / Loss after taxes and Minority Interest (15-16) | 9,421.40 | 4,019.58 | 97.60 | 13,267.90 | 812.80 |
| 18 | Paid up Equity Share Capital | 1,620.38 | 1,620.38 | 1620.38 | 1620.38 | 1,620.38 |
| 19 | Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year | - | - | - | 49,491.17 | 35,243.75 |
| 20 | Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised) | | | | | |
| (a) | Basic | 11.63 | 4.96 | 0.60 | 16.38 | 5.02 |
| (b) | Diluted | 11.28 | 4.81 | 0.58 | 15.89 | 4.87 |

1. The above Standalone Audited Financial Results for the Quarter & Year ended 31.03.2017 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 27.05.2017

2. The results shown above for the period ended with 31.03.2016 are of unamalgamated entity whereas the results for the other periods are of amalgamated entity. Hence the figures are not comparable.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

5. The income from divestiture of " certain products in speciality chemical division to Clariant India Limited" has been recognised.

6. The income from divestiture of Klarsehen business has been recognised.

Place : Hyderabad
Date : 27.05.2017

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR



VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED

Rs. in Lakhs

| Particulars | Quarter Ended | | | YEAR ENDED 31.03.2017 | YEAR ENDED 31-03-2016 |
|---|-------------------------|---------------------------|-------------------------|--------------------------|--------------------------|
| | 31.03.2017 (Audited) | 31.12.2016 (Unaudited) | 31.03.2016 (Audited) | | |
| 1. Segment Revenue (net sales/income from each segment should be disclosed under this head) | | | | | |
| a. Speciality Chemicals Business | 17,871.98 | 4,227.12 | 6,079.83 | 32,030.31 | 24,113.40 |
| b. Pharma Business | 4,736.44 | 9,725.30 | 1,873.75 | 24,953.46 | 7,825.96 |
| Total | 22,608.42 | 13,952.42 | 7,953.58 | 56,983.78 | 31,939.36 |
| Less, Inter Segment Revenue | | | | | |
| Net sales / Income from Operations | 22,608.42 | 13,952.42 | 7,953.58 | 56,983.78 | 31,939.36 |
| 2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment | | | | | |
| a. Speciality Chemicals Business | 13,383.23 | 1,013.92 | 1,184.10 | 19,398.06 | 5,918.33 |
| b. Pharma Business | 1,063.03 | 5,552.70 | 251.56 | 4,101.12 | 821.58 |
| Total | 14,446.26 | 6,566.62 | 1,435.66 | 23,499.18 | 6,739.90 |
| Less: 1. Interest | 1,431.92 | 1,362.26 | 1,200.03 | 5,354.99 | 5,605.93 |
| 2. Other Un-allocable Expenditure | | | | | |
| 3. Un-allocable Income | | | | | |
| Total Profit Before Tax | 13,014.34 | 5,204.35 | 235.63 | 18,144.20 | 1,133.97 |
| 3. Capital Employed | | | | | |
| a. Speciality Chemicals Business | 77,550.04 | 76,173.81 | 82,886.89 | 77,550.04 | 82,886.89 |
| b. Pharma Business | 38,873.91 | 54,378.81 | 38,708.06 | 38,873.91 | 38,708.06 |
| | 1,16,423.95 | 1,30,552.62 | 1,21,594.95 | 1,16,423.95 | 1,21,594.95 |
| 4. | | | | | |
| a. Segment Assets | 1,36,429.14 | 1,77,869.72 | 1,36,538.44 | 1,36,429.14 | 1,36,538.44 |
| b. Segment Liabilities | 81,517.55 | 1,21,913.06 | 99,574.31 | 81,517.55 | 99,574.31 |
| | | | | | |

Place : Hyderabad
Date : 27.05.2017



For VIVIMED LABS LIMITED
(SANTOSH VARALWAR)
MANAGING DIRECTOR

| S.No | Particulars | STANDALONE | | CONSOLIDATED | |
|------------|--|-------------------------|-------------------------|-------------------------|-------------------------|
| | | As at | As at | As at | As at |
| | | 31.03.2017 (Audited) | 31.03.2016 (Audited) | 31.03.2017 (Audited) | 31.03.2016 (Audited) |
| (A) | EQUITY AND LIABILITIES | | | | |
| 1 | Shareholders funds | | | | |
| | (a) Share Capital | | | | |
| | i) Equity Share Capital | 1,620.38 | 1,620.38 | 1,620.38 | 1,620.38 |
| | ii) Preference Share capital | | | | 6,394.56 |
| | (b) Reserves and Surplus | 53,291.17 | 35,343.75 | 70,769.33 | 50,500.31 |
| | (c) Money Received against Share Warrants | | | | |
| | Sub Total Shareholders Funds | 54,911.55 | 36,964.13 | 72,389.71 | 58,515.25 |
| 2 | Non-current liabilities | | | | |
| | a) Long-term borrowings | 18,831.02 | 19,303.22 | 45,269.63 | 25,726.94 |
| | (b) Deferred tax liabilities (net) | 3,236.96 | 3,253.67 | 963.50 | 1,069.94 |
| | (c) Other long-term liabilities | 9,024.10 | 32,103.98 | 5,980.66 | 28,956.50 |
| | (d) Long-term provisions | 355.86 | 338.18 | 362.84 | 357.29 |
| | Sub-total - Non-current liabilities | 31,447.95 | 54,999.05 | 52,576.62 | 56,110.66 |
| 3 | Current liabilities | | | | |
| | (a) Short-term borrowings | 30,064.56 | 29,190.58 | 37,640.75 | 40,775.95 |
| | (b) Trade payables | 4,050.17 | 2,444.97 | 15,241.03 | 16,673.97 |
| | (c) Other current liabilities | 8,531.42 | 11,408.28 | 18,624.96 | 28,585.38 |
| | (d) Short-term provisions | 7,423.59 | 1,531.43 | 10,079.19 | 3,705.61 |
| | Sub-total - Current liabilities | 50,069.75 | 44,575.25 | 81,585.93 | 89,740.91 |
| | TOTAL - EQUITY AND LIABILITIES | 1,36,429.25 | 1,36,538.43 | 2,06,552.26 | 2,04,366.82 |
| (B) | ASSETS | | | | |
| 1 | Non-current assets | | | | |
| | (a) Fixed assets | | | | |
| | (i) Tangible Assets | 38,212.13 | 37,623.54 | 65,287.59 | 71,490.93 |
| | (ii) Intangible Assets | 5,080.75 | 1,070.25 | 22,652.95 | 9,925.89 |
| | (iii) Capital work in progress | 5,864.06 | 4,082.88 | 7,612.59 | 9,416.91 |
| | (b) Non Current Investment | 8,326.55 | 23,004.55 | 252.00 | 268.92 |
| | (c) Long Term Loans and advances | | | | |
| | (d) Other Non Current Assets | 22.92 | | 23.20 | 4.39 |
| | Sub-total - Non-current assets | 57,506.41 | 65,781.23 | 95,828.33 | 91,107.05 |
| 2 | Current Assets | | | | |
| | (a) Inventories | 28,566.12 | 26,817.08 | 48,396.78 | 49,079.70 |
| | (b) Trade receivables | 22,685.61 | 23,085.96 | 20,214.35 | 32,624.08 |
| | (c) Cash and cash equivalents | 1,555.54 | 717.56 | 5,547.28 | 3,095.80 |
| | (d) Short-term loans and advances | 25,522.43 | 19,543.46 | 35,653.08 | 27,287.67 |
| | (e) Other current assets | 593.14 | 593.14 | 912.45 | 1,172.53 |
| | Sub-total - Current assets | 78,922.84 | 70,757.21 | 1,10,723.94 | 1,13,259.78 |
| | TOTAL - ASSETS | 1,36,429.25 | 1,36,538.44 | 2,06,552.26 | 2,04,366.82 |
| | | 0.00 | (0.01) | (0.00) | 0.00 |

Note :1. The figures shown above as at 31.03.2016 are of unamalgamated entity whereas the figures as at 31.03.2017 of Standalone are of amalgamated entity. Hence the figures are not comparable.





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com


Auditor's Report on Quarterly Consolidated Financial Results and Consolidated Year to Date Financial Results of Vivimed Labs Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

To
Board of Directors
Vivimed Labs Limited

We have audited the quarterly consolidated financial results of M/s Vivimed Labs Limited (the company) and its subsidiaries (collectively referred to as "TheGroup") for the quarter ended 31st March, 2017 and the consolidated year to date results for the period from 01st April, 2016 to 31st March, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The quarterly consolidated financial results and consolidated year to date financial results have been prepared from consolidated financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on the Consolidated financial results based on our audit of such Consolidated financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS) 25, specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements and financial information of twelve (12) Subsidiary Companies which is included in the consolidated quarterly financial results and consolidated year to date results, whose consolidated financial statements reflect total assets of Rs.23,87,70,09,325/- as at 31st March, 2017 as well as the total revenue of Rs.9,26,64,95,274/- as at 31st March, 2017. These include financial statements and other financial information which has been prepared by the management of respective companies and were furnished to us, our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such financial statements is based solely on the information received from Management.





P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com


In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date financial results:

1. Include the quarterly and year to date financial results of the following entity;
 - a) Finoso Pharma Pvt Ltd
 - b) Vivimed Labs USA Inc
 - c) Vivimed Labs Europe Ltd
 - d) Union QuimicoFarmaceutica SAU
 - e) Uquifa Mexico SA DE CV
 - f) Vivimed Holdings Ltd
 - g) Vivimed Labs UK Limited
 - h) Vivimed Labs Spain .S.L.
 - i) Vivimed Labs Mauritius Ltd
 - j) Holiday International Ltd
 - k) Vivimed Specialty Chemicals Private Limited
 - l) Vivimed Life Sciences Private Limited
2. have been presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosures Requirements) Regulations, 2015 in this regard; and
3. give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2017, as well as the year to date results for the period from 1st April 2016 to 31st March 2017.

For P. Murali & Co.,
Chartered Accountants
FRN: 007257S

P. Murali

P. Murali Mohana Rao
Partner
M No. 023412



Place: Hyderabad
Date: 27.05.2017



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.p murali.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of Vivimed Labs Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

To,
The Board of Directors
Vivimed Labs Limited

1. We have audited the quarterly financial results of M/s Vivimed Labs Limited for the quarter ended March 31, 2017 and to the year to date financial results for the year ended March 31, 2017, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2017 and the published year-to-date figures up to December 31, 2016, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2017 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2016, the audited annual financial statements as at and for the year ended March 31, 2017, and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Financial results based on our review of the financial results for the nine-month period ended December 31, 2016 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the companies (Accounts) Rules 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2017; and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





P. MURALI & CO.,


CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 in this regard; and
 - (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2017 as well as the year to date results for the period from April 1, 2016 to March 31, 2017.
4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2017 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2017 and the published year-to-date figures up to December 31, 2016, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
5. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of the Listing Agreement and found the same to be correct.

For P. Murali & Co.,
Chartered Accountants
Firm Registration number: 007257S

P. Murali Mohana Rao
P. Murali Mohana Rao
Partner
M.No 023412



Place: Hyderabad
Date: 27.05.2017



Vivimed

Date: 27/05/2017

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Sub.: Declaration – reg.


Ref: Regulation 33 of the SEBI (LODR) (Amendment) Regulations, 2016

Pursuant to the requirement as specified under Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI ((Listing Obligations and Disclosure Requirements) (amendment) Regulations 2016, it is hereby declared that the Auditors Report for the financial year ended as on March 31, 2017 contains unmodified opinion as provided under the independent Auditors Report which is attached herewith for your reference.

Please take the above on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For Vivimed Labs Ltd


Ramesh Challa
Chief Financial Officer



Vivimed Labs Ltd. (Corporate Office)

CIN: L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India.

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599







contact@vivimedlabs.com | www.vivimedlabs.com

FORM A

(For audit report on consolidated financial results with unmodified opinion)

| | | |
|---|--|------------------------------|
| 1 | Name of the Company | VIVIMED LABS LIMITED |
| 2 | Annual financial statements for the year ended | 31 st March, 2017 |
| 3 | Type of Audit observation | Un-modified |
| 4 | Frequency of observation | Not Applicable |

For Vivimed Labs Limited


Santosh Varalwar
Managing Director
(DIN: 00054763)
Ramesh Challa
Chief Financial Officer
Venkata Ratnam Paluri
Chairman of Audit Committee
(DIN: 02033493)
For P.Murali & Co.
Registration No. 00725
Chartered Accountants






Partner

FORM A

(For audit report on Standalone financial results with unmodified opinion)

| | | |
|---|--|------------------------------|
| 1 | Name of the Company | VIVIMED LABS LIMITED |
| 2 | Annual financial statements for the year ended | 31 st March, 2017 |
| 3 | Type of Audit observation | Un-modified |
| 4 | Frequency of observation | Not Applicable |

For Vivimed Labs Limited


Santosh Varadwar
Managing Director
(DIN: 00054763)
Ramesh Challa
Chief Financial Officer
Venkata Ratnam Paluri
Chairman of Audit Committee
(DIN: 02033493)
For P.Murali & Co.
Registration No. 00725
Chartered Accountants

Partner